This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
This is a single arm, prospective, multicenter post-approval study.
Study Type
OBSERVATIONAL
Enrollment
150
The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).
Children's of Alabama
Birmingham, Alabama, United States
Acute Device Success
Acute Device Success, defined as a non-hierarchical composite of: * Single Alterra deployed in the desired location * Single THV implanted in the desired location within Alterra * Right ventricle-pulmonary artery peak-to-peak gradient \< 35 mmHg post-THV implantation * Less than moderate total pulmonary regurgitation (PR) by discharge transthoracic echocardiogram * Free of Alterra/SAPIEN 3 explant at 24 hours post-implantation
Time frame: 24 hours post-procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arkansas Children's Hospital
Little Rock, Arkansas, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Rady Children's Hospital
San Diego, California, United States
Stanford University
Stanford, California, United States
Colorado Children's Hospital
Aurora, Colorado, United States
UF Health Shands Hospital
Gainesville, Florida, United States
St. Joseph's Children's Hospital
Tampa, Florida, United States
Advocate Children's Hospital
Oak Lawn, Illinois, United States
Boston Children's Hospital
Boston, Massachusetts, United States
...and 14 more locations